The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Changes in BMI Associated with Improvements in Disease Activity & Glucocorticoid Treatment

Changes in BMI Associated with Improvements in Disease Activity & Glucocorticoid Treatment

July 4, 2017 • By Arthritis Care & Research

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The authors note, “One of the strongest predictors of BMI change at six, 12 and 18 months that emerged from this analysis concerned whether the patient had a new diagnosis of AAV or was relapsing at baseline.” Patients newly diagnosed with AAV had an increased mean BMI (± SD) of 0.8 ± 0.3 kg/m2 (P=0.008) compared with patients with relapsing disease. Randomization to rituximab also emerged as a predictor of BMI change at Months 6 and 12. Rituximab-treated patients showed a mean (± SD) increase in BMI at Month 6 of 0.9 ± 0.3 kg/m2 compared with patients randomized to cyclophosphamide (P=0.002).

You Might Also Like
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Researchers were further able to determine that the change in BMI during the first six months of the RAVE trial were associated with disease activity, as reflected by BVAS/WG score, ESR and CRP level.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In some circumstances, it seems likely that the occurrence of weight gain implies effective disease control,” write the authors in their discussion. “In contrast, the failure of a patient on glucocorticoid treatment to gain weight augurs poorly for long-term disease control. In the absence of effective disease control, the weight loss associated with active disease trumps even glucocorticoid treatment. … It is only when the inflammation associated with AAV has been controlled that the full impact of glucocorticoid treatment on weight gain is realized.”

Although the factors that contribute to weight gain are complex and may be influenced by additional factors, the authors conclude that understanding the “factors mediating the relationship between glucocorticoid exposure and BMI variation is crucial to identifying and defining the significance and potential hazards of weight gain in the treatment of inflammatory conditions.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Read the full article.

Wallace ZS, Miloslavsky EM, Cascino M, et al. Disease activity, glucocorticoid exposure, and rituximab determine body composition changes during induction treatment of ANCA-associated vasculitis. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004–1010.

Pages: 1 2 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: ANCA-Associated Vasculitis, Arthritis Care & Research, BMI, body mass index (BMI), rituximab, weight gain, weight loss

You Might Also Like:
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis
  • Glucocorticoid-Induced Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.